Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, discusses results from a long-term follow-up of the Phase II MASTER trial (NCT03224507), which evaluated the outcomes of measurable residual disease (MRD)-adapted treatment cessation in patients with newly diagnosed multiple myeloma (NDMM) treated with daratumumab, carfilzomib, lenalidomide and dexamethasone (Dara-KRd). Dr Costa also highlights the impact of chromosomal abnormalities on patient outcomes and the need to implement novel therapies for patients with ultra-high-risk disease. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Sanofi: Consultancy, Honoraria; Adaptive Biotechnologies: Consultancy, Honoraria; Bristol Myers Squibb: Consultancy, Honoraria, Research Funding; Genentech: Research Funding; AbbVie: Research Funding; Amgen: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding.